In the original publication of the article, the Fig. 5 was published erroneously with mislabeling of the downregulating protein and duplication of an image in Fig. 5e. The corrected Fig. 5 shown below is the correct representation of the data from this study. The authors apologize for this error.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.